GlobeNewswire·Oct 5, 2025, 11:43 PM ET

UNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive

Faruqi & Faruqi, LLP is investigating potential securities law claims against Unicycive Therapeutics, Inc. (NASDAQ: UNCY) regarding false or misleading statements.
Investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, are encouraged to contact partner James (Josh) Wilson to discuss their legal options.
The October 14, 2025, deadline is set for investors to seek the role of lead plaintiff in the filed federal securities class action.
The complaint alleges the Company overstated its readiness to satisfy FDA manufacturing compliance requirements & overstated regulatory prospects for the OLC NDA.
On June 10, 2025, Unicycive disclosed FDA-identified cGMP deficiencies at a third-party subcontractor, causing stock to drop $3.68 (40.89%) to close at $5.32.
On June 30, 2025, the FDA issued a Complete Response Letter for the OLC NDA citing the same manufacturing deficiencies, causing stock to drop $2.03 (29.85%) to close at $4.77.
The firm invites whistleblowers, former employees, shareholders, and others with information regarding Unicycive's conduct to contact the firm.
The court-appointed lead plaintiff will direct litigation on behalf of the class, though participation is not required to share in any potential recovery.
Additional information & contact details are available at www.faruqilaw.com/UNCY or by calling 877-247-4292.